Recent Updates
Recently added Catalysts

Vepdegestrant

Phase 3FDA approved

Breast Cancer | Small Molecules | Oncology |Arvinas, Inc.|Trials Updated: Sep 29, 2026

Vepdegestrant development status

FDA approval on record May 1, 2026 as Veppanu
Approval holderArvinas Operations
ApplicationNDA219835
Highest phase Phase 3 run by Pfizer (NCT05654623)
Phase scored for ARVNPhase 1/2
Registered trials 17 across 3 sponsors since Aug 2019

Label indication VEPPANU is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 (ESR1) -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. FDA label

Vepdegestrant target and mechanism

Target class-Estrant (Serd)
ModalitySmall Molecules

Also known as ARV-471, PF-07850327

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment219

FDA Designations

FAST_TRACK

Vepdegestrant clinical trials

Vepdegestrant · 1 trial · 1 indication

Phase 1/2 1
NCT04072952A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast CancerBreast Cancer
COMPLETED219 Analytics
PHASE1/PHASE2COMPLETED
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
Breast CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Part A: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
Baseline (Day 1) up to C1D28

DLT was defined as any adverse event (AE) or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Treatment-Related TEAEs
From start of study treatment up to 30 days after end of study treatment (up to approximately 4 years and 6 months)

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. Serious AE (SAE) was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

Part B: Clinical Benefit Rate (CBR)
From start of study treatment until disease progression or death due to any cause (up to approximately 2 years and 11 months)

CBR: percentage of participants with summation of complete response (CR), partial response (PR) or stable disease (SD) of 24 weeks duration or longer. CR: disappearance of all target lesions (TLs) and non-TLs and normalization of tumor marker levels initially above upper limits of normal. PR: \>30% decrease in the sum of the longest diameter (LD) of TLs, taking as reference the baseline sum LD. SD of TLs was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum LD since the treatment started. SD of non-TLs Persistence of one or more non-TLs or/and maintenance of tumor marker level above the normal limits. PD: \>20% increase in the sum of the LD of TLs, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions and/or unequivocal progression of existing non-TLs.

Part C: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle of Treatment
Baseline (Day 1) up to C1D28

DLT was defined as any AE or abnormal laboratory value which were related to vepdegestrant and assessed as unrelated to mBC, intercurrent illness, or concomitant medications occurring during the first 28 days of treatment that met at least 1 of the study specified criteria.

Part C: Number of Participants With TEAEs, Serious TEAEs and Treatment-Related TEAEs
From start of study treatment up to 30 days after end of study treatment (up to approximately 3 years and 9 months)

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness was judged by investigator. SAE was an AE resulted in any of the following outcomes: death, inpatient hospitalization or prolongation of existing hospitalization; was life-threatening experience (immediate risk of dying); resulted in persistent or significant disability/incapacity; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was an AE occurring on/after the date of first dose of study medication and within 30 days of the last dose of study medication. TEAEs included both Serious TEAEs and non-serious TEAEs.

Part C: Maximum Tolerated Dose (MTD)
Baseline (Day 1) up to C1D28

MTD is the highest dose of a drug that can be given to participants without causing unacceptable DLTs, as determined during a clinical study.

Secondary Endpoints

Part A: Area Under the Concentration-Time Curve During a Dosing Interval (AUCtau) of Vepdegestrant and Its Epimer ARV-473
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1.
Part A: Area Under the Concentration-time Curve From Time 0 Through the Last Measurable Concentration (AUClast) of Vepdegestrant and Its Epimer ARV-473
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Part A: Maximum Observed Plasma Concentration (Cmax) of Vepdegestrant and Its Epimer ARV-473
Pre-dose, 1, 2, 4, 6, 8, 12 (optional) hours post dose on C1D1 and C1D15, and an additional sample at 24 hours post dose on C1D1
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part A - Phase 1: Vepdegestrant 30 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 30 milligrams (mg) orally once daily (QD) with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after the end of treatment (EOT) or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 60 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 60 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 100 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 100 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 120 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 120 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 180 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 180 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 200 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 360 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 360 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 500 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 500 mg QD or 250 mg twice daily (BID), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part A - Phase 1: Vepdegestrant 700 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 700 mg QD or as BID dose (400 mg in the morning and 300 mg in the evening), orally with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part B - Phase 2: Vepdegestrant 200 mg (Dose Expansion)EXPERIMENTALParticipants received vepdegestrant 200 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part B - Phase 2: Vepdegestrant 500 mg (Dose Expansion)EXPERIMENTALParticipants received vepdegestrant 500 mg orally QD with food in continuous daily dosing (on 28-day cycles). Vepdegestrant was administered in tablet form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part C - Phase 1b: Vepdegestrant 180 mg+ Palbociclib 125 mg (Dose Escalation)EXPERIMENTALParticipants initially received vepdegestrant 180 mg tablets orally QD with food then upon availability of the 100-mg tablets was rounded up to 200 mg QD, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed up for survival after at least 3 months after the EOT or Follow-up visit (whichever occurred later).
Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 125 mg (Dose Expansion)EXPERIMENTALParticipants received vepdegestrant 200 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part C - Phase 1b: Vepdegestrant 400 mg + Palbociclib 125 mg (Dose Escalation)EXPERIMENTALParticipants received vepdegestrant 400 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part C - Phase 1b: Vepdegestrant 500 mg + Palbociclib 125 mg (Dose Expansion)EXPERIMENTALParticipants received vepdegestrant 500 mg orally QD with food, given continuously (28-day cycle) in combination with palbociclib 125 mg orally QD for 21 days followed by 7 days off treatment to complete a 28-day cycle. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or Follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.
Part C - Phase 1b: Vepdegestrant 200 mg + Palbociclib 100 mg (Dose Expansion)EXPERIMENTALParticipants initially received palbociclib 100 mg orally QD starting on C1D1, for 21 days followed by 7 days off and then received vepdegestrant 200 mg QD with food on C1D9, given continuously (28-day cycle). Palbociclib was administered alone from C1D1 to C1D8 prior to starting vepdegestrant on C1D9. Vepdegestrant was administered in tablet form and palbociclib in capsule form. Treatment was continued at the investigator's discretion until disease progression, unacceptable toxicity, or withdrawal of consent occurred. Participants were followed for survival every 3 months after EOT or follow-up visit (whichever occurred later) until death, lost to follow-up, or withdrawal of consent.

Interventions

NameTypeDescription
VepdegestrantDRUGVepdegestrant administered QD for 28-day cycles
PalbociclibDRUGDaily oral dosages of vepdegestrant for 28 days in combination with palbociclib for 21 days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites16

Inclusion Criteria: Part A, Part B, and Part C: * Participants at least 18 years of age at the time of signing the informed consent. * Participants must have histologically or cytologically confirmed ER+ and HER2- advanced breast cancer for which standard curative therapy is no longer effective or...

Countries:United States
Unlock Eligibility Criteria

Competitive Landscape -Breast Cancer 601 trials

Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT04072952TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT04072952TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT04072952TRIAL_REMOVED: changed

Frequently asked questions about Vepdegestrant

What is vepdegestrant?

Vepdegestrant is an investigational small molecule developed by Arvinas, Inc. (ticker ARVN) for ER+/HER2- locally advanced or metastatic breast cancer. It is a targeted oral therapy studied both as a single agent and in combination with palbociclib (IBRANCE). It has received a FAST_TRACK designation from the FDA.

What is vepdegestrant used for in breast cancer?

Vepdegestrant is being studied for ER+/HER2- locally advanced or metastatic breast cancer. The clinical program enrolled adults 18 years and older with this biomarker-selected population. It was evaluated as monotherapy and in combination with palbociclib. It is investigational and has not been established as an approved treatment.

What does vepdegestrant target?

Vepdegestrant belongs to the -estrant class, also known as a selective estrogen receptor degrader (SERD). It targets the estrogen receptor, the driver of ER+ breast cancer growth. By degrading the receptor rather than only blocking it, the drug aims to reduce estrogen receptor signaling in ER+/HER2- tumors.

Who is developing vepdegestrant?

Vepdegestrant is being developed by Arvinas, Inc., which trades under the ticker ARVN. Arvinas is the sponsor of the clinical program evaluating the drug in ER+/HER2- locally advanced or metastatic breast cancer, including the combination study with palbociclib.

What phase is vepdegestrant in?

Vepdegestrant is in Phase 1 development. The Phase 1/2 trial of ARV-471 alone and in combination with palbociclib in ER+/HER2- locally advanced or metastatic breast cancer has been completed. The drug is investigational and is not FDA approved.

What clinical trials is vepdegestrant in?

Vepdegestrant has been studied in NCT04072952, a Phase 1/2 trial of ARV-471 alone and in combination with palbociclib (IBRANCE) in participants with ER+/HER2- locally advanced or metastatic breast cancer. The trial enrolled 219 participants in the United States and is completed. It was controlled but not randomized or double-blind.